Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study. …
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 Australian Biotech
Latest Video
New Stories
-
Another day, and another example of our system's shortcomings
July 21, 2025 - - Latest News -
Companies have all the power in this process, if they choose to use it
July 21, 2025 - - Latest News -
Trump says countries will avoid tariffs if manufacturing returns to the US
July 21, 2025 - - Latest News -
Mesoblast updates investors on the succesful US launch of cell medicine
July 20, 2025 - - Australian Biotech -
Company refuses FDA request to halt distribution of gene therapy
July 20, 2025 - - Latest News -
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast